Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about ROCHE HOLDING LTD.
01:53p ASTRAZENECA : among backers as Swiss cancer biotech raises $200 million
10:55a ROCHE : Chugai Pharmaceutical Co. Ltd. - F. Hoffmann La Roche Announces Third Qu..
10/20 INOVIO PHARMACEUTICALS : Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T..
10/19DJEuropean Corporate Roundup for Thursday
10/19DJEuropean Corporate Roundup for Thursday
10/19 ROCHE : Swiss biotech group Roche sees 5 pct rise in 9-month sales
10/19DJROCHE : 3Q Sales Increase on Strong Performance of Recently Launched Drugs
10/19 ROCHE : reports strong sales growth in the first nine months of 2017
10/18 FTSE rises to record close, blue-chips shrug off Reckitt blip
10/17 FOUNDATION MEDICINE : Study Shows Genomic Profiling Can Help Improve Treatment o..
10/16ROCHE HOLDING LTD. : quaterly sales release
10/16 ROCHE : to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsi..
10/16 GENENTECH : to Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data in Relap..
10/13 ROCHE : CHMP recommends EU approval of Roche's Alecensa (alectinib) as a first-l..
10/13DJROCHE : Gets CHMP Recommendation for Lung Cancer Treatment Alecensa
More most relevant news
All news about ROCHE HOLDING LTD.
01:53p ASTRAZENECA : among backers as Swiss cancer biotech raises $200 million
10:55a ROCHE : Chugai Pharmaceutical Co. Ltd. - F. Hoffmann La Roche Announces Third Qu..
10/20 ROCHE : 66-- Notice of Intent-Sole Source IDIQ Roche laboratory supplies
10/20 INOVIO PHARMACEUTICALS : Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T..
10/19 PTC THERAPEUTICS : Spinal Muscular Atrophy Program Advances into Pivotal Study i..
10/19 FOUNDATION MEDICINE : Appoints Tom Civik as Chief Commercial Officer
10/19DJEuropean Corporate Roundup for Thursday
10/19DJEuropean Corporate Roundup for Thursday
10/19 ROCHE : Swiss biotech group Roche sees 5 pct rise in 9-month sales
10/19DJROCHE : 3Q Sales Increase on Strong Performance of Recently Launched Drugs
More news
Sector news : Pharmaceuticals - NEC
03:13pDJEuropean Corporate Roundup for Monday
02:26pDJDrug Makers Find 'Branded Generics' Are a Source for Growth
01:53p ASTRAZENECA : among backers as Swiss cancer biotech raises $200 million
11:08a European shares flat as banks weigh, Spain lags again
11:03aDJEuropean Corporate Roundup for Monday
08:48aDJMERCK AND : to Shed Some U.S. Sales Reps -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/20 The Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 Roche Holding's (RHHBY) CEO Dr. Severin Schwan on Q3 2017 Results - Earnings ..
10/19 Roche Holding ADR (RHHBY) Updates On 3Q17 Sales - Slideshow
10/19 ROCHE Q3 2017 RESULTS : Some Weak Signals
Latest Tweets
03:46pCan cancer charity efforts from Roche, Bristol, AbbVie and more boost pharma'.. 
10/22Roche may be asking too much of its next generation of medicines
1
10/22$FMI - -$1.07 EPS Expected for Foundation Medicine, Inc. #FMI This Quarter  
10/22-$1.07 EPS Expected for Foundation Medicine, Inc. $FMI This Quarter  
10/22Contrasting Alkermes PLC $ALKS and Foundation Medicine $FMI  
More tweets
Qtime:340
Financials ( CHF)
Sales 2017 53 411 M
EBIT 2017 18 409 M
Net income 2017 11 152 M
Debt 2017 9 884 M
Yield 2017 3,67%
P/E ratio 2017 17,46
P/E ratio 2018 15,97
EV / Sales 2017 4,00x
EV / Sales 2018 3,78x
Capitalization 204 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 272  CHF
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.0.77%207 116
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
MERCK AND COMPANY8.51%174 223
AMGEN25.14%133 501